Phase 2 Study of CAN008 in Subjects With GBM

Summary

This is a multi-center, randomized, double-blind, placebo-controlled Phase 2 study whose objectives are to evaluate the clinical efficacy and safety of CAN008 plus TMZ during and after radiation therapy in newly-diagnosed subjects with glioblastoma who have undergone surgical excision.

Timeline

Start

2021-10-10

Primary completion

2024-01-31

Completion

2024-08-31

Drugs

Indications